TAU lab identifies effective antibodies from recovered Coronavirus patients

Written on |

Antibody-based therapies can be used to protect at-risk populations, including medical workers, from the virus

The race to develop effective antibody-based treatments for COVID-19 is advancing at a rapid pace. Now, a Tel Aviv University laboratory reports it has successfully isolated two antibodies that would neutralize the virus’s ability to infect human cells. The two suitable antibodies were identified in patients recovering from COVID-19, according to Dr. Natalia Freund who heads the Laboratory for Human Antibody Responses at TAU’s Sackler Faculty of Medicine. “The use of antibodies bears significant potential as a treatment for high-risk coronavirus patients and as a preventative measure for at-risk groups, like medical workers and essential employees, exposed to the virus,” she explains.

The weak link in the virus chain

In the long run, identifying effective antibodies against virus neutralization could also accelerate the development of vaccines for the disease. Dr. Freund, who together with her team pinpointed the antibodies in blood samples of recovering patients, say that antibodies would be key to identifying the elusive vulnerable Achilles’ heel of the virus, which scientists have identified as somewhere along its spike protein, the structure that allows it to break into a cell. Dr. Freund is collaborating with researchers in San Diego to test the efficacy of antibody treatments in animal models against a live active virus. The trials are scheduled to take place this month. Only if and when the trials are successful in animal models will the option of clinical trials be considered. “If we complete the trials successfully and are able to eventually develop this treatment, it could be used to help treat at-risk patients such as the elderly or immunocompromised patients. Antibodies can also remain active in the blood for many weeks – up to two months – so injecting antibodies can afford medical teams and other at-risk groups temporary protection against the virus.”

Related posts

Hyperbaric Treatment More Effective than Medicines for Fibromyalgia Caused by Head Injury

24 March 2023

Promoting Women in Medicine

9 March 2023

#TAU_WOMEN_POWER

7 March 2023

Researchers Discover Mechanism that Facilitates Formation of Brain Metastases

27 February 2023

Light Pollution is Killing Desert Rodents

10 February 2023

Three Tel Aviv University Researchers Awarded the ERC Proof of Concept (PoC) grants

9 February 2023

Researchers Identify A New Genetic Risk Factor for Age-related Eye Disease

8 February 2023

People With Autism Experience Pain at a Higher Intensity

31 January 2023

Researchers Uncover New Factors Linked to Williams Syndrome

24 January 2023

Lessons in Tolerance and DNA Extraction in Tel Aviv University’s Medical Labs

18 January 2023

Medical Clowns – No Laughing Matter

18 January 2023

Tel Aviv University’s First MedTech Hackathon Sets a High Bar

15 January 2023

Researchers use Smartwatches to Measure Safety of COVID Vaccine

28 December 2022

Tel Aviv University Establishes Multidisciplinary Center for Research of Autoimmune Diseases

18 December 2022

Breakthrough in the Field of Controlled Drug Delivery

16 December 2022

Common Medications May Reduce Risk of Metastases after Colon and Rectal Cancer

9 December 2022

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com